Pharmaceutical Companies

REGENXBIO Biogen Moderna Clinical Research Regenxbio Drug Testing Sarepta Therapeutics Drug Development Public Offerings Sinovant Sciences Market Development UniQure Vaccine Development Priovant Therapeutics Ocugen, Inc. Metabolic Health Clinical Development Capricor Therapeutics BBOT Executive Leadership Bavarian Nordic Market Analysis Regulatory Affairs Roivant Sciences Market Performance Covid-19 Vaccine Market Clinical Research Organizations

7 ARTICLES

last wk.

FDA Places Clinical Hold on REGENXBIO's RGX‑121 After Spine MRI Findings

Regulators have ordered additional imaging and longer follow‑up to determine whether the asymptomatic spinal nodules found in trial participants are linked to the AAV gene therapy which has paused near‑term approval plans.

3 ARTICLES

4mo ago

Avalo Therapeutics Reports Positive Phase 2 HS Results, Prices $375 Million Offering

3 ARTICLES

5mo ago

FDA Approves Higher‑Dose Spinraza Regimen for Spinal Muscular Atrophy

8 ARTICLES

6mo ago

Xenon to Present Topline X-TOLE2 Phase 3 Results in Focal Onset Seizures at 8 A.M. ET Today

6 ARTICLES

6mo ago

FDA Demands Placebo-Controlled Trial for UniQure’s Huntington’s Gene Therapy

3 ARTICLES

6mo ago

Ocugen Completes Phase III Enrollment for OCU400 and Targets Q3 2026 Rolling BLA

7 ARTICLES

6mo ago

FDA Rejects Filing of Moderna’s mRNA Flu Vaccine Over Comparator Dispute

4 ARTICLES

6mo ago

FDA Rejects Regenxbio’s Hunter Syndrome Gene Therapy Application

6 ARTICLES

11mo ago

Roivant’s Brepocitinib Succeeds in 52-Week Dermatomyositis Phase 3 as Companies Target 2026 FDA Filing

6 ARTICLES

last yr.

FDA Names George Tidmarsh Director of Center for Drug Evaluation and Research

8 ARTICLES

last yr.

Sarepta Halts Elevidys Shipments for Non-Ambulatory Patients After Second Fatal Liver Failure